Should you buy Seaport Therapeutics (SPTX)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Large Earnings Miss↓Deteriorating
- Heavy Insider Buying→Stable
- Favorable Risk Reward Asymmetry→Stable
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying
Trip ifInsider sell value exceeds $5,000,000 over a rolling 90-day window, reversing the current bullish signal.
- P2Favorable Risk Reward Asymmetry
Trip ifPrice falls below the $19.13 stop-loss, invalidating the 2.98x asymmetry setup.
- P3Weak Fundamental Quality
Trip ifPiotroski F-Score rises above 4 out of 9.
- P4Large Earnings Miss
Trip ifThe company's EPS surprise exceeds -20% at its next earnings release.
- P5Falling Volume Distribution
Trip ifOn-balance volume trend rises for more than 2 consecutive months.
How the engine reached this verdict
TrendMatrix's engine output for Seaport Therapeutics, Inc. (SPTX) is SELL_IF_HOLDING with medium conviction, score 5.7/10 at $21.30. Multiple gates have flipped against the verdict; the engine output is SELL.
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
On the bear side: Quality below floor (2.5 < 4.0). Active engine warnings: Quality below floor (2.5 < 4.0).
The engine's exit framework anchors to a tactical sell band near $21.30, with structural invalidation at $19.81. The asymmetric R:R against a reversal hypothesis is 3.68 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates SPTX — 10-dimension breakdown →
Bear case
- ▸Quality below floor (2.5 < 4.0)